Acute Myeloid Leukemia Treatment Market Summary

The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030, growing at a CAGR of 10.6% from 2025 to 2030. The increasing geriatric population base and growing unmet healthcare needs are expected to boost market growth further.

Key Market Trends & Insights

• North America acute myeloid leukemia treatment market dominated the global market with a share of 37.6% in 2024.

• The U.S. acute myeloid leukemia treatment market dominated the North America with a share of 90.9% in 2024.

• Based on disease, the myeloblastic leukemia segment accounted for the largest share of 43.0% in 2024.

• Based on treatment, the chemotherapy segment accounted for the largest share of 48.0% in 2024.

• Based on end-use, the hospitals and clinics segment accounted for the largest share of 52.5% in 2024.

Market Size & Forecast

• 2024 Market Size: USD 3.47 Billion

• 2030 Projected Market Size: USD 6.29 Billion

• CAGR (2025-2030): 10.6%

• North America: Largest market in 2023

• Asia Pacific: Fastest growing market

Rising incidences of acute myeloid leukemia and increasing need for advanced therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure.

Advancements in targeted therapies have been at the forefront of the progress in Acute Myeloid Leukemia (AML) treatment so far. In recent years, there has been substantial development in therapies such as BCL2 inhibitors, IDH inhibitors, and FLT3 inhibitors. These therapies provide personalized treatment options tailored to specific genetic mutations, resulting in improved outcomes for patients. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) for newly diagnosed FLT3-ITD positive acute myeloid leukemia in the U.S., enhancing treatment options alongside standard chemotherapy.

Global Acute Myeloid Leukemia Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global acute myeloid leukemia treatment market report based on disease, treatment, route of administration, end use, and region:

• Disease Outlook (Revenue, USD Million, 2018 - 2030)

  • Myeloblastic Leukemia

  • Myelomonocytic Leukemia

  • Promyelocytic Leukemia

  • Monocytic Leukemia

  • Other Diseases

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

    • Anti-metabolites

    • Alkylating Agents

    • Anthracycline Drugs

    • Others

  • Targeted Therapy

    • FLT3 Inhibitors

      • Rydapt

      • Vanflyta

      • Xospata

    • IDH Inhibitors

      • Tibsovo

      • Rezlidhia

      • Idhifa

    • Mylotarg

    • BCL-2 Inhibitor

    • Hedgehog Pathway Inhibitor

  • Immunotherapy

    • Bispecific Antibodies

    • Antibody-drug Conjugates

    • Immune Checkpoint Inhibitors

    • Chimeric Antigen Receptor (CAR) T-cell Therapy

  • Other Treatments

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Parenteral

  • Oral

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals and Clinics

  • Specialty Centers

  • Homecare Setting

  • Ambulatory Care Centers